Medlive Technology Co., Ltd. (MEDLIVE) expanded its issued share base by 602,875 shares in March 2026 through the exercise of options under its Pre-IPO Share Option Scheme. The newly issued shares lifted the company’s total outstanding ordinary shares to 738.96 million as of 31 March 2026, up from 738.36 million a month earlier.

The exercised options, priced at RMB 0.38 each, generated RMB 0.23 million in cash proceeds. Following the transaction, 1.31 million options remain outstanding under the Pre-IPO scheme. The Post-IPO Share Option Scheme, adopted on 18 June 2021, had no outstanding options during the period but still allows for the future issuance of up to 69.02 million shares.

Authorised share capital stayed unchanged at 50 billion ordinary shares with a par value of USD 0.00001 each, representing total authorised capital of USD 500,000.

Medlive reported zero treasury shares throughout the period and confirmed compliance with the minimum public-float requirement of 24.98 % as stipulated by Hong Kong listing rules.